How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

5,258 results for

adhd exercise

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

5201. Effectiveness of Combined Medication Treatment for Aggression in Children With Attention Deficit With Hyperactivity Disorder (The SPICY Study)

the advantages and disadvantages of adding one of two different types of drugs to stimulant treatment for reducing aggressive behavior in children with attention deficit with hyperactivity disorder (ADHD). Condition or disease Intervention/treatment Phase Attention Deficit Disorder With Hyperactivity Drug: Valproate Drug: Risperidone Drug: Placebo Drug: Stimulant medication Behavioral: Behavioral family counseling Phase 4 Detailed Description: Attention deficit with hyperactivity disorder (ADHD) is a common (...) Blader, National Institute of Mental Health (NIMH): Attention-Deficit/Hyperactivity Disorder Aggressive Behavior Oppositional Defiant Disorder Conduct Disorder Additional relevant MeSH terms: Layout table for MeSH terms Disease Attention Deficit Disorder with Hyperactivity Hyperkinesis Aggression Pathologic Processes Attention Deficit and Disruptive Behavior Disorders Neurodevelopmental Disorders Mental Disorders Dyskinesias Neurologic Manifestations Nervous System Diseases Signs and Symptoms

2008 Clinical Trials

5202. Atomoxetine for Treating Marijuana-Abusing Adolescents Who Have Attention Deficit Hyperactivity Disorder

ADHD. In addition, this study will assess whether atomoxetine reduces ADHD symptoms as compared to a placebo. Finally, the study will determine whether atomoxetine improves treatment retention and progress in adolescents with ADHD and marijuana dependence. Condition or disease Intervention/treatment Phase Attention Deficit Disorder With Hyperactivity Marijuana Abuse Drug: Atomoxetine Other: placebo Phase 2 Detailed Description: Attention Deficit Hyperactivity Disorder (ADHD) is common among (...) for MeSH terms Disease Attention Deficit Disorder with Hyperactivity Hyperkinesis Marijuana Abuse Pathologic Processes Attention Deficit and Disruptive Behavior Disorders Neurodevelopmental Disorders Mental Disorders Dyskinesias Neurologic Manifestations Nervous System Diseases Signs and Symptoms Substance-Related Disorders Chemically-Induced Disorders Atomoxetine Hydrochloride Adrenergic Uptake Inhibitors Neurotransmitter Uptake Inhibitors Membrane Transport Modulators Molecular Mechanisms

2005 Clinical Trials

5203. A Safety and Effectiveness Study of JNJ-31001074 in Adults With Attention-Deficit/Hyperactivity Disorder.

Last Update Posted: May 13, 2014 Last Verified: April 2014 Keywords provided by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.: Attention Deficit Hyperactivity Disorder ADHD JNJ-31001074 Additional relevant MeSH terms: Layout table for MeSH terms Disease Attention Deficit Disorder with Hyperactivity Hyperkinesis Pathologic Processes Attention Deficit and Disruptive Behavior Disorders Neurodevelopmental Disorders Mental Disorders Dyskinesias Neurologic Manifestations Nervous System (...) : May 13, 2014 Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Information provided by (Responsible Party): Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Study Details Study Description Go to Brief Summary: The purpose of this study is to evaluate the safety and effectiveness of JNJ-31001074 compared to placebo in adults with Attention Deficit Hyperactivity Disorder (ADHD). Condition or disease Intervention/treatment Phase Attention Deficit Hyperactivity

2007 Clinical Trials

5204. Study of Adderall-XR for the Treatment of Adult Attention Deficit Hyperactivity Disorder and Cocaine Dependence

(NIDA): ADHD Cocaine Treatment Additional relevant MeSH terms: Layout table for MeSH terms Disease Attention Deficit Disorder with Hyperactivity Hyperkinesis Cocaine-Related Disorders Pathologic Processes Attention Deficit and Disruptive Behavior Disorders Neurodevelopmental Disorders Mental Disorders Dyskinesias Neurologic Manifestations Nervous System Diseases Signs and Symptoms Substance-Related Disorders Chemically-Induced Disorders Cocaine Amphetamine Adderall Anesthetics, Local Anesthetics (...) Intervention/treatment Phase Adult Attention Deficit Hyperactivity Disorder Cocaine Dependence Drug: Placebo Drug: Adderall-XR Phase 2 Phase 3 Detailed Description: Specific Aim 1: To determine the efficacy of ER-MAS in promoting cocaine abstinence and ADHD improvement among comorbid ADHD and cocaine-dependent patients. Primary Hypothesis: benzoylecgonine positive urine screens will decrease with greatest to least reductions from 80mg>60mg>PBO (placebo). Hypothesis 2: ADHD-Rating Scale will decrease

2007 Clinical Trials

5205. Organizational Skills Training for Children With Attention Deficit Hyperactivity Disorder

Deficit Disorder With Hyperactivity Behavioral: Organizational Skills Training Behavioral: Contingency management (CM) Not Applicable Detailed Description: Attention deficit hyperactivity disorder (ADHD) is one of the most common mental disorders among children. Children with ADHD frequently lack organizational, time management, and planning skills. These deficits can cause impaired functioning in multiple settings, including home, school, and peer relationships. Advancements in treatment options (...) Information: Layout table for additonal information Responsible Party: Howard Abikoff, Director, Institute for Attention Deficit Hyperactivity and Behavior Disorders, New York University School of Medicine ClinicalTrials.gov Identifier: Other Study ID Numbers: DDTR B2-NDH First Posted: September 27, 2006 Last Update Posted: April 19, 2013 Last Verified: April 2013 Keywords provided by Howard Abikoff, New York University School of Medicine: ADHD Organizational Skills Contingency Management Additional

2006 Clinical Trials

5206. Single Versus Combination Medication Treatment for Children With Attention Deficit Hyperactivity Disorder

) First Posted: January 31, 2007 Results First Posted: June 14, 2017 Last Update Posted: June 14, 2017 Last Verified: May 2017 Keywords provided by James McCracken, University of California, Los Angeles: ADHD Guanfacine Methylphenidate Focalin XR Pediatric Cognitive function Combination therapy Additional relevant MeSH terms: Layout table for MeSH terms Attention Deficit Disorder with Hyperactivity Hyperkinesis Attention Deficit and Disruptive Behavior Disorders Neurodevelopmental Disorders Mental (...) First Posted : June 14, 2017 Last Update Posted : June 14, 2017 Sponsor: University of California, Los Angeles Collaborator: National Institute of Mental Health (NIMH) Information provided by (Responsible Party): James McCracken, University of California, Los Angeles Study Details Study Description Go to Brief Summary: This study will evaluate the effectiveness of a single drug versus a combination of drugs in treating attention deficit hyperactivity disorder in children. Condition or disease

2007 Clinical Trials

5207. Atomoxetine for Treating Attention Deficit Hyperactivity Disorder in Young Children

: University of Nebraska Collaborator: National Institute of Mental Health (NIMH) Information provided by (Responsible Party): Christopher J. Kratochvil, M.D., University of Nebraska Study Details Study Description Go to Brief Summary: This study will evaluate the effectiveness of atomoxetine in reducing the symptoms of attention deficit hyperactivity disorder (ADHD) in young children. Condition or disease Intervention/treatment Phase Attention Deficit Disorder With Hyperactivity Drug: Atomoxetine Drug (...) : Placebo Behavioral: Parent Training Phase 4 Detailed Description: Attention deficit hyperactivity disorder (ADHD) is one of the most common mental disorders in children. Children with ADHD often have impaired functioning in home and school and usually experience difficulty relating to peers. If left untreated, the disorder can have long-term adverse effects into adolescence and adulthood. Atomoxetine is a selective noradrenergic reuptake inhibitor that is FDA-approved for the treatment of ADHD

2005 Clinical Trials

5208. Long-term Safety and Effectiveness of OROS Methylphenidate HCl in Children With Attention Deficit Hyperactivity Disorder

Corporation, DE, USA: ADHD Attention Deficit Hyperactivity Disorder OROS® children methylphenidate Additional relevant MeSH terms: Layout table for MeSH terms Attention Deficit Disorder with Hyperactivity Hyperkinesis Attention Deficit and Disruptive Behavior Disorders Neurodevelopmental Disorders Mental Disorders Dyskinesias Neurologic Manifestations Nervous System Diseases Signs and Symptoms Methylphenidate Central Nervous System Stimulants Physiological Effects of Drugs Dopamine Uptake Inhibitors (...) Posted : December 26, 2005 Last Update Posted : June 14, 2011 Sponsor: Alza Corporation, DE, USA Information provided by: Alza Corporation, DE, USA Study Details Study Description Go to Brief Summary: The purpose of this study is to evaluate the long-term safety and effectiveness of OROS® Methylphenidate HCl (a central nervous system stimulant) in children with attention deficit hyperactivity disorder (ADHD). Condition or disease Intervention/treatment Phase Attention Deficit Hyperactivity Disorder

2005 Clinical Trials

5209. A Multicenter Study Comparing the Efficacy and Safety of OROS Methylphenidate HCl, Ritalin (Methylphenidate HCl) and Placebo in Children With Attention Deficit Hyperactivity Disorder

and standard immediate-release Ritalin® (taken three time per day) for the treatment of Attention Deficit Hyperactivity Disorder in children. Both OROS® Methylphenidate HCl and Ritalin® contain the central nervous system stimulant, methylphenidate HCl. Condition or disease Intervention/treatment Phase Attention Deficit Hyperactivity Disorder Drug: OROS methylphenidate HCl Drug: Ritalin Drug: Placebo Phase 3 Detailed Description: Attention Deficit Hyperactivity Disorder (ADHD) represents the most common (...) methylphenidate Additional relevant MeSH terms: Layout table for MeSH terms Attention Deficit Disorder with Hyperactivity Hyperkinesis Attention Deficit and Disruptive Behavior Disorders Neurodevelopmental Disorders Mental Disorders Dyskinesias Neurologic Manifestations Nervous System Diseases Signs and Symptoms Methylphenidate Central Nervous System Stimulants Physiological Effects of Drugs Dopamine Uptake Inhibitors Neurotransmitter Uptake Inhibitors Membrane Transport Modulators Molecular Mechanisms

2005 Clinical Trials

5210. An Effectiveness and Safety Study Evaluating OROS Methylphenidate Hydrochloride (HCl), Ritalin (Methylphenidate HCl) and Placebo in Children With Attention Deficit Hyperactivity Disorder

(HCl) formulation compared to placebo and standard immediate-release Ritalin with respect to improving attention and behavior, and decreasing hyperactivity in children with Attention Deficit Hyperactivity Disorder (ADHD). Both OROS Methylphenidate HCl and Ritalin contain the central nervous system stimulant, methylphenidate HCl. The safety associated with the two methylphenidate formulations will also be compared with placebo. Condition or disease Intervention/treatment Phase Attention Deficit (...) Numbers: CR005989 CONCERTAATT3019 C-98-003-02 First Posted: December 26, 2005 Last Update Posted: July 11, 2011 Last Verified: July 2011 Keywords provided by Alza Corporation, DE, USA: ADHD Attention Deficit Hyperactivity Disorder OROS children methylphenidate Ritalin Additional relevant MeSH terms: Layout table for MeSH terms Attention Deficit Disorder with Hyperactivity Hyperkinesis Attention Deficit and Disruptive Behavior Disorders Neurodevelopmental Disorders Mental Disorders Dyskinesias

2005 Clinical Trials

5211. Psychosocial Treatment for Attention Deficit Hyperactivity Disorder in Adults

Intervention/treatment Phase Attention Deficit Disorder With Hyperactivity Behavioral: Meta-Cognitive Therapy Behavioral: Supportive Therapy Not Applicable Detailed Description: ADHD is a chronic neurobiological condition that affects people of all ages, genders, and races. Symptoms of ADHD may include, but are not limited to, the following: poor attention span; physical restlessness or hyperactivity; excessive impulsivity; chronic procrastination; frequently losing things; poor organization, planning (...) at Mount Sinai Collaborator: National Institute of Mental Health (NIMH) Information provided by (Responsible Party): Icahn School of Medicine at Mount Sinai Study Details Study Description Go to Brief Summary: This study will determine the effectiveness of group cognitive-behavioral therapy as compared to a problem-solving social support group in treating problems of time management, organization, and planning in adults with attention deficit hyperactivity disorder (ADHD). Condition or disease

2006 Clinical Trials

5212. Stimulant Versus Nonstimulant Medication for Attention Deficit Hyperactivity Disorder in Children

Last Update Posted : June 6, 2018 Sponsor: Icahn School of Medicine at Mount Sinai Collaborator: National Institute of Mental Health (NIMH) Information provided by (Responsible Party): Jeffrey Newcorn, Icahn School of Medicine at Mount Sinai Study Details Study Description Go to Brief Summary: This study will determine the effectiveness of stimulant and nonstimulant medication in treating the symptoms of attention deficit hyperactivity disorder (ADHD) in children and adolescents. Condition (...) or disease Intervention/treatment Phase Attention Deficit Disorder With Hyperactivity Drug: Atomoxetine Drug: Methylphenidate Phase 4 Detailed Description: ADHD is one of the most frequently occurring disorders of children and adolescents and is a significant public health problem. The most common treatment for the condition is stimulant medication. However, there are an increasing number of children who are experiencing negative side effects from stimulants, such as dizziness, loss of appetite

2005 Clinical Trials

5213. Methylphenidate for Attention Deficit Hyperactivity Disorder and Autism in Children

of methylphenidate in improving cognitive and behavioral outcomes in children with both ASD and ADHD. Condition or disease Intervention/treatment Phase Autism Attention Deficit Disorder With Hyperactivity Drug: Methylphenidate-extended release Drug: Methylphenidate-immediate release Other: Placebo Phase 2 Phase 3 Detailed Description: Attention Deficit Hyperactivity Disorder (ADHD) is a major comorbid psychiatric disorder in children with Autism Spectrum Disorders (ASD) that significantly undermines behavioral (...) Center, Houston ClinicalTrials.gov Identifier: Other Study ID Numbers: DDTR B2-NDA First Posted: September 15, 2005 Results First Posted: May 7, 2013 Last Update Posted: May 9, 2013 Last Verified: May 2013 Additional relevant MeSH terms: Layout table for MeSH terms Autistic Disorder Attention Deficit Disorder with Hyperactivity Hyperkinesis Autism Spectrum Disorder Child Development Disorders, Pervasive Neurodevelopmental Disorders Mental Disorders Attention Deficit and Disruptive Behavior Disorders

2005 Clinical Trials

5214. Modafinil in children and adolescents with attention-deficit/hyperactivity disorder: a preliminary 8-week, open-label study. (Abstract)

Modafinil in children and adolescents with attention-deficit/hyperactivity disorder: a preliminary 8-week, open-label study. In a 4-week, double-blind, placebo-controlled study, the attention-promoting agent modafinil improved symptoms of attention-deficit/hyperactivity disorder (ADHD) in children and adolescents and was well tolerated. To assess the continued efficacy of modafinil and obtain additional safety data, an 8-week, open-label study was conducted as an extension to the double-blind (...) ) in the Inattention and Hyperactivity-impulsivity scores, respectively. The mean Total score [SD] on the CADS-P decreased from baseline (74.4 [10.3]) to the final visit (63.2 [13.1]) (change: -11.2, 95% CI: -13.08 to -9.65). Fifty-three percent of patients were rated as much or very much improved on the CGI-I. Insomnia (13%) and headache (10%) were the most common adverse events. No clinically meaningful changes were observed in physical examination findings, electrocardiography, blood pressure, pulse, or body

2006 Current medical research and opinion Controlled trial quality: uncertain

5215. A comprehensive approach to treating autism and attention-deficit hyperactivity disorder: a prepilot study. (Abstract)

A comprehensive approach to treating autism and attention-deficit hyperactivity disorder: a prepilot study. The purpose of this study was to observe the effects of a multi dimensional treatment plan involving nutrition, environmental control, chelation, and behavioral/educational/physical/speech therapy to treat children with autistic spectrum disorder and attention-deficit hyperactivity (ADHD) disorder. This study is only a preliminary study, and its small size (10 patients) precludes (...) in addition to their usual behavioral, educational, speech, and physical therapies.Study outcomes were measured by objective/subjective improvement as judged by physicians/parents/teachers. Outcomes were also measured by changes in urinary heavy metal burdens over time.All 10 children showed significant improvement in many areas of social interaction, concentration, writing, language, and behavior. Urinary lead burden dropped significantly in all 10 children.Autistic spectrum disorders and ADHD

2007 Journal of Alternative and Complementary Medicine

5216. Allergic rhinitis in children with attention-deficit/hyperactivity disorder. (Abstract)

Allergic rhinitis in children with attention-deficit/hyperactivity disorder. Both allergic rhinitis and attention-deficit/hyperactivity disorder (ADHD) are common pediatric conditions associated with learning difficulties and sleep disturbances. There are conflicting research data regarding the association between ADHD and atopic disorders.To determine the prevalence of allergic rhinitis in patients with physician-diagnosed ADHD.Patients 5 to 18 years of age who presented with a Diagnostic (...) and Statistical Manual of Mental Disorders, Fourth Edition diagnosis of ADHD to an outpatient pediatric psychiatry clinic were screened for allergic rhinitis with focused history, physical examination, and skin prick testing to common aeroallergens.Thirty patients were interviewed, with 23 of these undergoing physical examination and skin prick testing. Eighty percent reported allergic rhinitis symptoms, whereas 61% had at least 1 positive prick skin test result. Forty-three percent showed typical physical

2004 Asthma & Immunology

5217. Implementing the American Academy of Pediatrics attention-deficit/hyperactivity disorder diagnostic guidelines in primary care settings. Full Text available with Trip Pro

Implementing the American Academy of Pediatrics attention-deficit/hyperactivity disorder diagnostic guidelines in primary care settings. To evaluate the feasibility of the San Diego Attention-Deficit/Hyperactivity Disorder Project (SANDAP) protocol, a pediatric community-initiated quality improvement effort to foster implementation of the American Academy of Pediatrics (AAP) attention-deficit/hyperactivity disorder (ADHD) diagnostic guidelines, and to identify any additional barriers (...) , including quantitative surveys with parents and teachers and qualitative debriefing sessions conducted an average of 3 times per year with pediatricians and office staff members.Between December 2000 and April 2003, 159 children were consecutively enrolled for evaluation of school and/or behavioral problems. Clinically, only 44% of the children met criteria for ADHD on both the parent and teacher scales, and 73.5% of those children were categorized as having the combined subtype. More than 40

2004 Pediatrics

5218. Self-regulation of slow cortical potentials: a new treatment for children with attention-deficit/hyperactivity disorder. Full Text available with Trip Pro

their excitation threshold. This training aims at regulation of cortical excitation thresholds considered to be impaired in children with attention-deficit/hyperactivity disorder. Electroencephalographic data from the training and the 6-month follow-up are reported, as are changes in behavior and cognition.Twenty-three children with attention-deficit/hyperactivity disorder aged between 8 and 13 years received 30 sessions of self-regulation training of slow cortical potentials in 3 phases of 10 sessions each (...) are reported. Measurement before and after the trials showed that children with attention-deficit/hyperactivity disorder learn to regulate negative slow cortical potentials. After training, significant improvement in behavior, attention, and IQ score was observed. The behavior ratings included Diagnostic and Statistical Manual of Mental Disorders criteria, number of problems, and social behavior at school and were conducted by parents and teachers. The cognitive variables were assessed with the Wechsler

2006 Pediatrics

5219. Worse quality of life for children with newly diagnosed attention-deficit/hyperactivity disorder, compared with asthmatic and healthy children. Full Text available with Trip Pro

Worse quality of life for children with newly diagnosed attention-deficit/hyperactivity disorder, compared with asthmatic and healthy children. To evaluate the quality of life (QOL) of untreated children with newly diagnosed attention-deficit/hyperactivity disorder (ADHD), compared with asthmatic and healthy children.This prospective, case-control study included a group of 120 children, 6 to 12 years of age, with newly diagnosed ADHD according to the Diagnostic and Statistical Manual of Mental (...) Disorders, Fourth Edition. Subjects were matched according to age, gender, and health care area with 2 control groups, ie, 93 asthmatic children and 120 healthy children. Sociodemographic characteristics and Child Health Questionnaire scores were collected.The QOL of children with ADHD was rated worse than that of asthmatic or healthy children for most Child Health Questionnaire domains. The greatest differences were found in behavior, social limitations attributable to physical problems, emotional

2005 Pediatrics

5220. Health-related quality of life in children and adolescents who have a diagnosis of attention-deficit/hyperactivity disorder. Full Text available with Trip Pro

Health-related quality of life in children and adolescents who have a diagnosis of attention-deficit/hyperactivity disorder. The aim of treatment for attention-deficit/hyperactivity disorder (ADHD) is to decrease symptoms, enhance functionality, and improve well-being for the child and his or her close contacts. However, the measurement of treatment response is often limited to measuring symptoms using behavior rating scales and checklists completed by teachers and parents. Because so much (...) (BE), emotional impact on parent (PTE), and time impact on parents (PTT). A separate domain measures limitations in family activities (FA). There is also a single-item measure of family cohesion (FC). Individual scale scores and summary scores for physical (PhS) and psychosocial health (PsS) can be computed. Symptom severity data (parent and teacher) came from the Child/Adolescent Symptom Inventory 4. These checklists provide information on symptoms for the 3 ADHD subtypes (inattentive, hyperactive

2004 Pediatrics

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>